RNA Medicine Finds Its Way Into Muscle

Sarepta's siRNA data confirm muscle-targeted RNA delivery is clinically viable for the first time, opening a new front in rare neuromuscular disease

13 Apr 2026

For years, RNA medicines have been confined, in effect, to the liver. Delivery systems capable of shuttling small interfering RNA into hepatic cells have advanced rapidly, but reaching skeletal muscle at useful concentrations has proved far harder. New clinical data from Sarepta Therapeutics indicate that may be changing.

On March 25th the American biotech presented first-in-human results from two investigational programmes targeting rare neuromuscular diseases. SRP-1001 aims to silence the DUX4 gene in facioscapulohumeral muscular dystrophy type 1 (FSHD1); SRP-1003 targets toxic DMPK messenger RNA accumulation in myotonic dystrophy type 1 (DM1). Both drugs, in ascending-dose Phase 1/2 trials, showed dose-dependent drug exposure in muscle tissue, early signs that the target genes were being suppressed, and no dose-limiting toxicity.

Both treatments are built on the TRiM delivery platform, licensed exclusively from Arrowhead Pharmaceuticals. The system uses a ligand that binds to αvβ6 integrin receptors on skeletal muscle cells to direct siRNA to its intended destination. Notably, no saturation of muscle uptake has been observed, implying that higher therapeutic doses may still be within reach as trials progress.

The implications for the field extend beyond Sarepta's pipeline. Confirming that a systemically administered RNA construct can reach non-hepatic tissue in humans, with dose-proportional pharmacokinetics and measurable biological effects, validates a delivery approach that has been discussed in theory for years. For FSHD1 and DM1, two conditions for which no disease-modifying therapy has been approved, the data represent a genuine shift in clinical prospects.

Caveats remain, and they are significant. Phase 1/2 trials are designed to assess safety and early activity, not to prove that patients feel or function better. Larger, longer studies will be required before any regulatory filing could be contemplated. The distance between encouraging biomarker data and a medicine that works in practice is one the industry has crossed far less often than investors might hope.

Still, demonstrating that RNA can reliably reach muscle in humans is the kind of foundational result that tends to reorder a field's priorities. If the approach holds, it opens the door to targets in the lung and central nervous system as well. The liver, long RNA medicine's comfort zone, may soon have company.